LLY
Eli Lilly and Company · Healthcare · Drug Manufacturers - General
Momentum girdileri (karşılaştırılabilir yöneticiler):
hissedar genişliği +9.1% ·
pay akışı -2.3% ·
net yeni pozisyonlar +8.3%
— formül
Sahiplik parçalanması — daha fazla hissedar, daha küçük toplam pay
Tüm sahiplik rakamları: yalnızca izlenen 13F yöneticileri, adi hisse senedi pozisyonları, raporlama dönemi Q3 2024
| Çeyrek | Hissedarlar | Δ | Hisseler | Raporlanan değer | Yeni | Çıkışlar |
|---|---|---|---|---|---|---|
| Q2 2026 | 193 | +4 | 671.92M | $804.91B | +6 | −1 |
| Q1 2026 | 191 | -3 | 666.59M | $613.20B | +1 | −5 |
| Q4 2025 | 193 | +2 | 707.04M | $758.81B | +3 | — |
| Q3 2025 | 27 | -3 | 329.88M | $251.63B | +2 | −6 |
| Q2 2025 | 28 | -1 | 307.45M | $239.60B | +2 | −3 |
| Q1 2025 | 26 | 0 | 140.32M | $115.83B | +1 | −1 |
| Q4 2024 | 26 | +1 | 145.00M | $111.91B | +3 | −2 |
| Q3 2024 | 24 | +2 | 109.89M | $97.29B | +2 | — |
| Q2 2024 | 22 | — | 112.43M | $101.75B | — | — |
| # | Yönetici | Hisseler | Δ hisseler | Değer | Ağırlıkları | Tutulan | ||
|---|---|---|---|---|---|---|---|---|
| 1 | T. Rowe Price ✦ | 20.93M | +1.4% | $18.54B | 2.1% | ▲ Add | 2 | SEC ↗ |
| 2 | T. Rowe Price ✦ | 20.93M | +1.4% | $18.54B | 2.1% | ▲ Add | 2 | SEC ↗ |
| 3 | Capital World Investors ✦ | 20.36M | -6.7% | $18.03B | 2.8% | ▼ Trim | 2 | SEC ↗ |
| 4 | PRIMECAP Management ✦ | 17.69M | -9.8% | $15.67B | 11.5% | ▼ Trim | 2 | SEC ↗ |
| 5 | Geode Capital Management ✦ (pasif) | 17.09M | +0.5% | $15.09B | 1.2% | ▲ Add | 2 | SEC ↗ |
| 6 | Geode Capital Management ✦ (pasif) | 17.09M | +0.5% | $15.09B | 1.2% | ▲ Add | 2 | SEC ↗ |
| 7 | Wellington Management ✦ | 10.61M | -1.5% | $9.40B | 1.6% | ▼ Trim | 2 | SEC ↗ |
| 8 | Wellington Management ✦ | 10.61M | -1.5% | $9.40B | 1.6% | ▼ Trim | 2 | SEC ↗ |
| 9 | Wellington Management ✦ | 10.61M | -1.5% | $9.40B | 1.6% | ▼ Trim | 2 | SEC ↗ |
| 10 | Wellington Management ✦ | 10.61M | -1.5% | $9.40B | 1.6% | ▼ Trim | 2 | SEC ↗ |
| 11 | Wellington Management ✦ | 10.61M | -1.5% | $9.40B | 1.6% | ▼ Trim | 2 | SEC ↗ |
| 12 | Wellington Management ✦ | 10.61M | -1.5% | $9.40B | 1.6% | ▼ Trim | 2 | SEC ↗ |
| 13 | Wellington Management ✦ | 10.61M | -1.5% | $9.40B | 1.6% | ▼ Trim | 2 | SEC ↗ |
| 14 | Wellington Management ✦ | 10.61M | -1.5% | $9.40B | 1.6% | ▼ Trim | 2 | SEC ↗ |
| 15 | Wellington Management ✦ | 10.61M | -1.5% | $9.40B | 1.6% | ▼ Trim | 2 | SEC ↗ |
| 16 | Norges Bank ✦ (pasif) | 10.49M | -4.7% | $9.29B | 1.3% | ▼ Trim | 2 | SEC ↗ |
| 17 | Fisher Asset Management ✦ | 5.06M | +3.5% | $4.48B | 1.8% | ▲ Add | 2 | SEC ↗ |
| 18 | Arrowstreet Capital ✦ | 1.63M | +1.3% | $1.44B | 1.2% | ▲ Add | 2 | SEC ↗ |
| 19 | Millennium Management ✦ | 990.21K | +86.1% | $877.27M | 0.8% | ▲ Add | 2 | SEC ↗ |
| 20 | Tiger Global Management ✦ | 969.80K | +4.3% | $859.18M | 3.7% | ▲ Add | 2 | SEC ↗ |
| 21 | Marshall Wace ✦ | 910.13K | +15.3% | $806.32M | 1.1% | ▲ Add | 2 | SEC ↗ |
| 22 | Marshall Wace ✦ | 910.13K | +15.3% | $806.32M | 1.1% | ▲ Add | 2 | SEC ↗ |
| 23 | Marshall Wace ✦ | 910.13K | +15.3% | $806.32M | 1.1% | ▲ Add | 2 | SEC ↗ |
| 24 | Adage Capital Partners ✦ | 829.38K | +0.2% | $734.78M | 1.3% | ▲ Add | 2 | SEC ↗ |
| 25 | AQR Capital Management ✦ | 677.64K | +42.8% | $591.79M | 0.8% | ▲ Add | 2 | SEC ↗ |
| 26 | AQR Capital Management ✦ | 677.64K | +42.8% | $591.79M | 0.8% | ▲ Add | 2 | SEC ↗ |
| 27 | AQR Capital Management ✦ | 677.64K | +42.8% | $591.79M | 0.8% | ▲ Add | 2 | SEC ↗ |
| 28 | AQR Capital Management ✦ | 677.64K | +42.8% | $591.79M | 0.8% | ▲ Add | 2 | SEC ↗ |
| 29 | AQR Capital Management ✦ | 677.64K | +42.8% | $591.79M | 0.8% | ▲ Add | 2 | SEC ↗ |
| 30 | D. E. Shaw & Co. ✦ | 408.08K | +72.0% | $361.54M | 0.5% | ▲ Add | 2 | SEC ↗ |
| 31 | D. E. Shaw & Co. ✦ | 408.08K | +72.0% | $361.54M | 0.5% | ▲ Add | 2 | SEC ↗ |
| 32 | Renaissance Technologies ✦ | 257.81K | Yeni | $228.41M | 0.3% | New | 1 | SEC ↗ |
| 33 | Coatue Management ✦ | 247.95K | +19.8% | $219.67M | 0.8% | ▲ Add | 2 | SEC ↗ |
| 34 | Coatue Management ✦ | 247.95K | +19.8% | $219.67M | 0.8% | ▲ Add | 2 | SEC ↗ |
| 35 | Coatue Management ✦ | 247.95K | +19.8% | $219.67M | 0.8% | ▲ Add | 2 | SEC ↗ |
| 36 | Coatue Management ✦ | 247.95K | +19.8% | $219.67M | 0.8% | ▲ Add | 2 | SEC ↗ |
| 37 | Coatue Management ✦ | 247.95K | +19.8% | $219.67M | 0.8% | ▲ Add | 2 | SEC ↗ |
| 38 | Citadel Advisors ✦ | 215.18K | -57.0% | $190.64M | 0.2% | ▼ Trim | 2 | SEC ↗ |
| 39 | Citadel Advisors ✦ | 215.18K | -57.0% | $190.64M | 0.2% | ▼ Trim | 2 | SEC ↗ |
| 40 | Two Sigma Investments ✦ | 199.74K | -11.5% | $176.95M | 0.4% | ▼ Trim | 2 | SEC ↗ |
| 41 | Viking Global Investors ✦ | 152.04K | +5.5% | $134.70M | 0.5% | ▲ Add | 2 | SEC ↗ |
| 42 | Bridgewater Associates ✦ | 73.27K | -23.5% | $64.91M | 0.4% | ▼ Trim | 2 | SEC ↗ |
| 43 | Dodge & Cox ✦ | 45.09K | -1.9% | $39.95M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 44 | GAMCO Investors ✦ | 34.81K | -2.8% | $30.84M | 0.3% | ▼ Trim | 2 | SEC ↗ |
| 45 | Point72 Asset Management ✦ | 13.16K | Yeni | $11.66M | 0.0% | New | 1 | SEC ↗ |
| 46 | Gotham Asset Management ✦ | 8.52K | -28.7% | $7.54M | 0.1% | ▼ Trim | 2 | SEC ↗ |
"Yöneticinin ağırlığı" = pozisyonun, ilgili yöneticinin raporlanan 13F hisse senedi değeri içindeki payı — kanaat ölçütü. ✦ = küratörlü yönetici.
Yeni alıcılar
| Renaissance Technologies | $228.41M | 0.3% |
| Point72 Asset Management | $11.66M | 0.0% |
Çıkıldı
| Bu çeyrekte takip edilen çıkış yok. |
Tam piyasa bağlamı: TÜM 13F filers'ları genelinde (SEC yapılandırılmış veri, Q1 2026): 4,323 sahipler, 762.84M hisseler, $674.93B raporlanan. Bu, yukarıdaki takip edilen evren rakamlarından farklı, daha eski bir döneme aittir ve ikisi hiçbir zaman birbirine karıştırılmaz.
Bu menkul kıymetin takip edilen yatırımcılarının en sık birlikte elinde bulundurduğu diğer varlıklar — ortak sahiplik sayımları, temel ilişkiler değil.
Açık piyasa alımları (P)
Kapsama penceremizde açık piyasa içeriden alım işlemi yok.
Açık piyasa satışları (S)
Officer · 6.50K hisse · $7.64M
Officer · 2.00K hisse · $2.37M
Officer · 5.00K hisse · $5.95M
Ödüller, kullanımlar ve vergi stopajı hiçbir zaman alım veya satım olarak sayılmaz. Metodoloji
The Food and Drug Administration has cleared a new blood test from Roche and Eli Lilly designed to help identify…
ForbesThe Food and Drug Administration cleared a blood test for identifying Alzheimer's disease symptoms, which was developed…
WSJThe U.S. Food and Drug Administration has cleared Roche and partner Eli Lilly's blood test to help identify signs of…
ReutersThe once-daily pill was approved for patients with a body mass index of at least 30, or between 27 and 30 in the event…
WSJEli Lilly said on Monday it has launched its oral pill, Foundayo, in the UK for weight management and type 2…
Reuters